



GETTING STARTED

WITH VIZIMPRO[®] (DACOMITINIB)

VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic).

- VIZIMPRO is used as a first treatment if tumors have certain types of abnormal epidermal growth factor receptor (EGFR) gene(s).

Your healthcare provider will perform a test to make sure that VIZIMPRO is right for you. It is not known if VIZIMPRO is safe and effective in children.

VIZIMPRO may cause side effects which can be serious. **Please see Important Safety Information on pages 30-31.**

Please see Important Safety Information on pages 30-31.
Click for the [Full Prescribing Information](#) and [Patient Information](#)
or visit VIZIMPRO.com.



VIZIMPRO[®]
DACOMITINIB
45mg, 30mg, 15mg tablets



**MAKING YOUR
FIRST MOVE
WITH VIZIMPRO[®] (DACOMITINIB)**

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

INDICATION

VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic).

- VIZIMPRO is used as a first treatment if tumors have certain types of abnormal epidermal growth factor receptor (EGFR) gene(s).

Your healthcare provider will perform a test to make sure that VIZIMPRO is right for you. It is not known if VIZIMPRO is safe and effective in children.

SELECTED SAFETY INFORMATION

VIZIMPRO may cause serious side effects, including:

- **Lung or breathing problems.** VIZIMPRO may cause severe inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing or shortness of breath, cough, or fever.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.





A GUIDE TO SUPPORT YOU THROUGH YOUR TREATMENT

Learning that you have non-small cell lung cancer (NSCLC) is life-changing—you may feel shocked, angry, or overwhelmed.

As you process your diagnosis, it's important to remember that you didn't do anything wrong. This is not your fault, and you're not alone. You might be feeling scared but learning more about NSCLC and your treatment plan may help you feel like you are regaining control.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](https://www.vizimpro.com).

Treatment will now be part of your daily routine. Your healthcare provider performed a test to make sure that VIZIMPRO® (dacomitinib) is right for you, and has prescribed VIZIMPRO because it's designed to treat your specific type of metastatic NSCLC, which has certain abnormal, or mutated, epidermal growth factor receptor (EGFR) **genes**. VIZIMPRO is a prescription medicine used to treat NSCLC that has spread to other parts of the body (metastatic). It is used as your first treatment if your tumor has certain types of EGFR mutations.

In this brochure, you will find information about metastatic NSCLC as well as treatment with VIZIMPRO.

Each person with lung cancer has unique needs. Keep this brochure handy, as you may want to refer to it if you have questions or seek resources that may address your individual needs.

Information here does not replace advice from your healthcare team; always consult them with any questions.

SELECTED SAFETY INFORMATION

VIZIMPRO may cause serious side effects, including:

- **Diarrhea.** Diarrhea is common during treatment with VIZIMPRO, and can be severe and lead to death. Diarrhea can cause you to lose too much body fluid (dehydration). Your healthcare provider may tell you to start drinking more fluids or start taking your anti-diarrheal medicines. Tell your healthcare provider right away, if you have any loose stools or have stools more often than is normal for you.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](https://www.vizimpro.com).





Please see Important Safety Information on pages 30-31.
Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

Doctor portrayal.

VIZIMPRO® (dacomitinib) may cause serious side effects, including:

- **Lung or breathing problems.** VIZIMPRO may cause severe inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing or shortness of breath, cough, or fever
- **Diarrhea.** Diarrhea is common during treatment with VIZIMPRO, and can be severe and lead to death. Diarrhea can cause you to lose too much body fluid (dehydration). Your healthcare provider may tell you to start drinking more fluids or start taking your anti-diarrheal medicines. Tell your healthcare provider right away, if you have any loose stools or have stools more often than is normal for you
- **Skin reactions.** Skin reactions are common with VIZIMPRO and can be severe. These skin reactions may include: dry skin, redness, rash, acne, itching, and peeling or blistering of your skin. Use moisturizers every day when taking VIZIMPRO. Use sunscreen and wear protective clothing that covers your skin, while exposed to sunlight, while you are taking VIZIMPRO. Your healthcare provider may prescribe other medicines to help skin reactions. Tell your healthcare provider right away about any worsening skin reactions

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.





TABLE OF CONTENTS

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and Patient Information or visit VIZIMPRO.com.

About non-small cell lung cancer (NSCLC)	10
EGFR mutations	12
Your treatment plan	14
What is VIZIMPRO® (dacomitinib)?	16
How does VIZIMPRO work?	17
How was VIZIMPRO studied?	18
What was seen with VIZIMPRO in the clinical study?	21
What are the possible side effects of VIZIMPRO?	24
How is VIZIMPRO taken?	28
Important Safety Information	30
Getting VIZIMPRO	33
Resources	34
Glossary	35

EGFR=epidermal growth factor receptor.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.





ABOUT NON-SMALL CELL LUNG CANCER

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. In some cases, it can spread to other parts of your body. If this happens, it is called metastatic NSCLC.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.



Types of metastatic NSCLC

NSCLC is divided into different types depending on the genetic changes that caused it to form and that fuel its growth; one type of genetic change is called a **mutation**. There are many possible genetic mutations that can cause NSCLC to form. These mutations are what make the tumor cells grow and multiply abnormally.



Biomarkers

Biomarkers are signs of these mutations. By testing a sample of your tumor or blood for biomarkers, your doctor can learn if your cancer has certain mutations. This is called **biomarker testing**, but it may also be referred to as **genetic testing** or **molecular testing**.

With this information, your doctor will know more about your type of cancer. It will also help inform your overall treatment plan and shed light on which type of treatment may work best in slowing or stopping cancer growth.

If you test positive for a biomarker, your healthcare provider may recommend a **biomarker-driven treatment** for your cancer. Biomarker-driven treatments are thought to work by blocking the effects of the mutations that are making the cancer cells grow. This is why it's important to know which biomarker your tumor may have.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](https://www.vizimpro.com).

EGFR IS ONE OF THE MOST COMMON BIOMARKERS IN NSCLC

One of the most common biomarkers for people with NSCLC is called **epidermal growth factor receptor**, or EGFR.

EGFR is mutated in **about 10% of people with NSCLC in the US**

People with NSCLC who test positive for EGFR mutations are said to have EGFR-positive NSCLC. Although EGFR-positive NSCLC can happen to anyone, it's more common in women and people who have never smoked.

INDICATION

VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic).

- VIZIMPRO is used as a first treatment if tumors have certain types of abnormal epidermal growth factor receptor (EGFR) gene(s).

Your healthcare provider will perform a test to make sure that VIZIMPRO is right for you. It is not known if VIZIMPRO is safe and effective in children.



Please see Important Safety Information on pages 30-31. Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](https://www.vizimpro.com).

About EGFR and EGFR-positive NSCLC treatments

We now understand that, for people with EGFR-positive NSCLC, mutations in the EGFR gene cause the EGFR protein within certain lung cells to be turned on and act in an uncontrolled way. This causes the cells to grow and divide without restrictions, leading to cancer.

The EGFR gene can change in different ways to cause NSCLC. The 2 most common EGFR-activating mutations are called “exon 19 deletion” and the “L858R substitution in exon 21.”



45% of people with EGFR-positive NSCLC have the “exon 19 deletion”



40% of people with EGFR-positive NSCLC have the “L858R substitution in exon 21”

Because your metastatic NSCLC tested positive for either an EGFR exon 19 deletion mutation or the L858R substitution in exon 21 mutation, your doctor has started your treatment plan with VIZIMPRO® (dacomitinib)—an oral medicine called an EGFR inhibitor. EGFR inhibitors are biomarker-driven treatments that work by blocking the abnormal EGFR protein that causes tumor cells to grow and divide.

EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer.

SELECTED SAFETY INFORMATION

VIZIMPRO may cause serious side effects, including:

- **Skin reactions.** Skin reactions are common with VIZIMPRO and can be severe. These skin reactions may include: dry skin, redness, rash, acne, itching, and peeling or blistering of your skin. Use moisturizers every day when taking VIZIMPRO. Use sunscreen and wear protective clothing that covers your skin, while exposed to sunlight, while you are taking VIZIMPRO. Your healthcare provider may prescribe other medicines to help skin reactions. Tell your healthcare provider right away about any worsening skin reactions.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](#).





Please see Important Safety Information on pages 30-31.
Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

WHAT IS MY TREATMENT PLAN?

As you plan to begin your first EGFR-inhibitor therapy, it may be helpful to talk with your doctor about your overall treatment strategy.

Most people with EGFR-positive NSCLC will start their treatment plan with an EGFR inhibitor. Some people may receive chemotherapy before their EGFR inhibitor. While receiving treatment, your healthcare provider will periodically monitor your disease to see how your treatment is working.

Once on therapy, your first treatment may stop working, and your cancer may start to grow or spread again. This is called *progression*. It means that the tumor found ways to grow and survive despite treatment. Progression can be caused by a new mutation, so your doctor may perform a molecular test again to determine your treatment options.

You play an important role in your treatment plan, and it's important to work with your doctor to map out how you move ahead if progression occurs. Having open and honest conversations with your doctor will help create a treatment plan that best meets your needs.

EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.





WHAT IS VIZIMPRO?

VIZIMPRO® (dacomitinib) is a prescription medicine designed to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) and is used as a first treatment if tumors have certain abnormal epidermal growth factor receptor (EGFR) genes. Your healthcare provider will perform a test to make sure that VIZIMPRO is right for you.

It is not known if VIZIMPRO is safe and effective in children.

SELECTED SAFETY INFORMATION

Before taking VIZIMPRO, tell your healthcare provider about all your medical conditions, including if you:


- have frequent diarrhea.
- have a history of lung or breathing problems other than lung cancer.
- are pregnant, or plan to become pregnant. VIZIMPRO can harm your unborn baby.

Please see Important Safety Information on pages 30-31. Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

HOW DOES VIZIMPRO WORK?

VIZIMPRO attaches to EGFR proteins, blocking signals that help cells grow.

This may help shrink or slow the growth of NSCLC tumors with the EGFR exon 19 deletion mutation or the L858R substitution in exon 21 mutation. VIZIMPRO can also affect normal cells, which may contribute to some of the side effects.



SELECTED SAFETY INFORMATION

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with VIZIMPRO.
- You should use effective birth control (contraception) during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about birth control methods that may be right for you during this time.
- Tell your healthcare provider right away if you become pregnant during your treatment with VIZIMPRO.
- are breastfeeding or plan to breastfeed. It is not known if VIZIMPRO passes into your breast milk. Do not breastfeed during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about the best way to feed your baby during this time.


Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.



HOW WAS VIZIMPRO STUDIED?

VIZIMPRO® (dacomitinib) was compared to another EGFR inhibitor (gefitinib) in a *head-to-head* clinical study. This type of study provides a direct comparison of the safety and effectiveness of the 2 treatments.



SELECTED SAFETY INFORMATION

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VIZIMPRO and other medicines or supplements may affect each other causing side effects.

What should I avoid during treatment with VIZIMPRO?

Minimize exposure to sunlight. VIZIMPRO can cause skin reactions.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

Adults in the study either had:

- No prior therapy for their EGFR-positive NSCLC that had spread to other parts of the body, or
- EGFR-positive NSCLC that came back after at least 12 months without detectable cancer following a past therapy

Effectiveness of the 2 treatments was measured in a few different ways:

- How long people lived without their cancer growing or spreading (**progression-free survival**)
- How many people had their tumors shrink (**overall response rate**)
- How long responses lasted before tumors resumed growing or spreading (**duration of response**)
- The overall length of time people lived (**overall survival**)

EGFR=epidermal growth factor receptor; NSCLC=non-small cell lung cancer.

SELECTED SAFETY INFORMATION

The most common side effects of VIZIMPRO include:

- rash
- diarrhea
- mouth pain and sores
- nail inflammation
- common cold
- dry skin
- decreased appetite
- decreased weight
- dry, red, itchy eyes
- hair loss
- itching

These are not all of the possible side effects of VIZIMPRO. You can ask your pharmacist or healthcare provider for more information about VIZIMPRO that is written for health professionals.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.






Please see Important Safety Information on pages 30-31.
Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

WHAT WAS SEEN WITH VIZIMPRO IN THE CLINICAL STUDY?

Progression-free survival: Time without cancer growing or spreading



The *median* is the “middle number” in a list of numbers ordered from lowest to highest. In this case, the median time to disease progression was 14.7 months, so half of people who took VIZIMPRO experienced disease progression before 14.7 months and half of people experienced disease progression after 14.7 months.

SELECTED SAFETY INFORMATION

VIZIMPRO may cause serious side effects, including:

- **Lung or breathing problems.** VIZIMPRO may cause severe inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing or shortness of breath, cough, or fever.


Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.



ADDITIONAL FINDINGS FROM THE CLINICAL STUDY

Overall response rate



In this study, scientists could not take a formal measurement of the effect of VIZIMPRO on overall survival (how long people lived) vs gefitinib. Overall survival could only be formally assessed if *significantly* more people taking VIZIMPRO saw their tumors shrink (overall response rate) compared to people taking gefitinib. There were no significant differences in overall response rates between VIZIMPRO and gefitinib, and therefore, no official test could be conducted to compare survival.

SELECTED SAFETY INFORMATION

VIZIMPRO may cause serious side effects, including:


- **Diarrhea.** Diarrhea is common during treatment with VIZIMPRO, and can be severe and lead to death. Diarrhea can cause you to lose too much body fluid (dehydration). Your healthcare provider may tell you to start drinking more fluids or start taking your anti-diarrheal medicines. Tell your healthcare provider right away, if you have any loose stools or have stools more often than is normal for you.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

Among people whose tumors shrank, those taking VIZIMPRO experienced more time before tumors began to grow again (duration of response) compared with people taking gefitinib.

Median duration of response



SELECTED SAFETY INFORMATION


VIZIMPRO may cause serious side effects, including:

- **Skin reactions.** Skin reactions are common with VIZIMPRO and can be severe. These skin reactions may include: dry skin, redness, rash, acne, itching, and peeling or blistering of your skin. Use moisturizers every day when taking VIZIMPRO. Use sunscreen and wear protective clothing that covers your skin, while exposed to sunlight, while you are taking VIZIMPRO. Your healthcare provider may prescribe other medicines to help skin reactions. Tell your healthcare provider right away about any worsening skin reactions.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.





As you begin treatment with VIZIMPRO® (dacomitinib), it can be helpful to learn more about what to expect, including potential side effects.

Please see Important Safety Information on pages 30-31.
Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF VIZIMPRO?

The serious side effects and most common side effects are presented here. If you think you may be experiencing these or other side effects while taking VIZIMPRO, be sure to tell your healthcare provider right away.

If you experience side effects, your healthcare team may do one or a combination of the following:



Add a medicine to help lessen the severity of the side effect



Temporarily stop treatment with VIZIMPRO



Change the dose of VIZIMPRO

In some cases, if a side effect doesn't improve with these strategies, you may have to permanently stop taking VIZIMPRO.

In a study, 150 of the 227 people taking VIZIMPRO (66%) had their dose adjusted after experiencing side effects; also due to side effects, 129 people receiving VIZIMPRO (57%) had to temporarily stop taking the drug, and 41 (18%) had to permanently stop taking VIZIMPRO.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.



VIZIMPRO[®]
DACOMITINIB
45mg, 30mg, 15mg tablets

SERIOUS SIDE EFFECTS




Lung or breathing problems

- VIZIMPRO® (dacomitinib) may cause severe inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer
- Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing or shortness of breath, cough, or fever



Diarrhea

- Diarrhea is common during treatment with VIZIMPRO, and can be severe and lead to death
- Diarrhea can cause you to lose too much body fluid (dehydration). Your healthcare provider may tell you to start drinking more fluids or start taking your anti-diarrheal medicines
- Tell your healthcare provider right away, if you have any loose stools or have stools more often than is normal for you



Skin reactions

- Skin reactions are common with VIZIMPRO and can be severe
- These skin reactions may include: dry skin, redness, rash, acne, itching, and peeling or blistering of your skin
- Use moisturizers every day when taking VIZIMPRO. Use sunscreen and wear protective clothing that covers your skin, while exposed to sunlight, while you are taking VIZIMPRO
- Your healthcare provider may prescribe other medicines to help skin reactions. Tell your healthcare provider right away about any worsening skin reactions

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

MOST COMMON SIDE EFFECTS

The most common side effects of VIZIMPRO include:

- rash
- decreased appetite
- diarrhea
- decreased weight
- mouth pain and sores
- dry, red, itchy eyes
- nail inflammation
- hair loss
- common cold
- itching
- dry skin

These are not all of the possible side effects of VIZIMPRO.

Call your doctor for medical advice about side effects.
You may report side effects to the FDA at 1-800-FDA-1088.

What should I avoid during treatment with VIZIMPRO?

Minimize exposure to sunlight.
VIZIMPRO can cause skin reactions.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](#).



VIZIMPRO[®]
DACOMITINIB
45mg, 30mg, 15mg tablets

HOW IS VIZIMPRO TAKEN?

VIZIMPRO® (dacomitinib) is a once-daily oral treatment option

The recommended starting dose of VIZIMPRO is 45 mg once daily. VIZIMPRO is also available in 30-mg and 15-mg tablets.



Not actual size.

SELECTED SAFETY INFORMATION

Before taking VIZIMPRO, tell your healthcare provider about all your medical conditions, including if you:

- have frequent diarrhea.
- have a history of lung or breathing problems other than lung cancer.
- are pregnant, or plan to become pregnant. VIZIMPRO can harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with VIZIMPRO.
- You should use effective birth control (contraception) during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about birth control methods that may be right for you during this time.
- Tell your healthcare provider right away if you become pregnant during your treatment with VIZIMPRO.
- are breastfeeding or plan to breastfeed. It is not known if VIZIMPRO passes into your breast milk. Do not breastfeed during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about the best way to feed your baby during this time.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](https://www.vizimpro.com).

HOW TO TAKE VIZIMPRO

- Take VIZIMPRO exactly as your healthcare provider tells you



Take your dose at approximately the same time each day



Take VIZIMPRO 1 time each day **with or without food**



If you take an antacid or H2 blocker medicine during treatment with VIZIMPRO, take your dose of VIZIMPRO at least 6 hours before or 10 hours after taking the antacid or H2 blocker medicine

- Do not change your dose or stop taking VIZIMPRO unless your healthcare provider tells you
- If you vomit or miss a dose of VIZIMPRO, do not take another dose or make up for the missed dose. Take your next dose at your regular time
- Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with VIZIMPRO if you have side effects

As always, it's important to keep your doctor aware of how you're feeling. While you're taking VIZIMPRO, be sure to be on the lookout for any side effects and communicate them to your doctor right away.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.



IMPORTANT SAFETY INFORMATION

VIZIMPRO® (dacomitinib) may cause serious side effects, including:

- **Lung or breathing problems.** VIZIMPRO may cause severe inflammation of the lung that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you have any new or worsening lung symptoms, including trouble breathing or shortness of breath, cough, or fever.
- **Diarrhea.** Diarrhea is common during treatment with VIZIMPRO, and can be severe and lead to death. Diarrhea can cause you to lose too much body fluid (dehydration). Your healthcare provider may tell you to start drinking more fluids or start taking your anti-diarrheal medicines. Tell your healthcare provider right away, if you have any loose stools or have stools more often than is normal for you.
- **Skin reactions.** Skin reactions are common with VIZIMPRO and can be severe. These skin reactions may include: dry skin, redness, rash, acne, itching, and peeling or blistering of your skin. Use moisturizers every day when taking VIZIMPRO. Use sunscreen and wear protective clothing that covers your skin, while exposed to sunlight, while you are taking VIZIMPRO. Your healthcare provider may prescribe other medicines to help skin reactions. Tell your healthcare provider right away about any worsening skin reactions.

Before taking VIZIMPRO, tell your healthcare provider about all your medical conditions, including if you:

- have frequent diarrhea.
- have a history of lung or breathing problems other than lung cancer.
- are pregnant, or plan to become pregnant. VIZIMPRO can harm your unborn baby.

Females who are able to become pregnant:

- Your healthcare provider should do a pregnancy test before you start treatment with VIZIMPRO.
- You should use effective birth control (contraception) during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about birth control methods that may be right for you during this time.
- Tell your healthcare provider right away if you become pregnant during your treatment with VIZIMPRO.
- are breastfeeding or plan to breastfeed. It is not known if VIZIMPRO passes into your breast milk. Do not breastfeed during treatment and for at least 17 days after your last dose of VIZIMPRO. Talk to your healthcare provider about the best way to feed your baby during this time.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](https://www.vizimpro.com).

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. VIZIMPRO and other medicines or supplements may affect each other causing side effects.

What should I avoid during treatment with VIZIMPRO?

Minimize exposure to sunlight. VIZIMPRO can cause skin reactions.

The most common side effects of VIZIMPRO include:

- rash
- diarrhea
- mouth pain and sores
- nail inflammation
- common cold
- dry skin
- decreased appetite
- decreased weight
- dry, red, itchy eyes
- hair loss
- itching

These are not all of the possible side effects of VIZIMPRO. You can ask your pharmacist or healthcare provider for more information about VIZIMPRO that is written for health professionals.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

INDICATION

VIZIMPRO is a prescription medicine used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic).

- VIZIMPRO is used as a first treatment if tumors have certain types of abnormal epidermal growth factor receptor (EGFR) gene(s).

Your healthcare provider will perform a test to make sure that VIZIMPRO is right for you. It is not known if VIZIMPRO is safe and effective in children.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](https://www.vizimpro.com).



Making your support needs a priority. Together.

Managing day-to-day life after diagnosis can be overwhelming, but you don't have to do it alone. Pfizer Oncology Together™ is a support program that treats your individual needs as a priority.



Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit [VIZIMPRO.com](https://www.vizimpro.com).

GETTING VIZIMPRO[®] (dacomitinib)

VIZIMPRO FINANCIAL ASSISTANCE

Finding financial support options. **Together.**



COMMERCIALLY INSURED

Resources for eligible commercial, private, employer, or state health insurance marketplace coverage:

- Co-pay assistance: Eligible, commercially insured patients may pay as little as \$0 per month for VIZIMPRO. Limits, terms, and conditions apply.* There are no income requirements, forms, or faxing to enroll

*Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico. Patients may receive up to \$25,000 in savings per product annually. **The offer will be accepted only at participating pharmacies. This offer is not health insurance.** No membership fees apply. Pfizer reserves the right to rescind, revoke, or amend this offer without notice. For full Terms and Conditions, please see PfizerOncologyTogether.com/terms. For any questions, please call 1-877-744-5675, visit PfizerOncologyTogether.com/terms or write: Pfizer Oncology Together Co-Pay Savings Program, 2250 Perimeter Park Drive, Suite 300, Morrisville, NC 27560.



FOR LIVE, PERSONALIZED SUPPORT

Call **1-877-744-5675** (Monday–Friday 8 AM–8 PM ET)

VISIT

PfizerOncologyTogether.com

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.



RESOURCES



LUNGevity Foundation

The LUNGevity Foundation is dedicated to funding lung cancer research and providing free education and patient support services to people living with lung cancer. The foundation also hosts an extensive online community for patients and caregivers.

www.lungevity.org



GO₂ Foundation for Lung Cancer

Founded by patients and survivors, GO₂ Foundation for Lung Cancer transforms survivorship as the world's leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer. They work to change the reality of living with lung cancer by ending stigma, increasing public and private research funding, and ensuring access to care.

www.go2foundation.org



The Lung Cancer Research Foundation

The Lung Cancer Research Foundation is dedicated to improving lung cancer outcomes by funding research for the prevention, diagnosis, treatment, and cure of lung cancer. In addition, the organization offers awareness and educational programs and brings the lung cancer community together through Free to Breathe Walks and other events nationwide. For more information, visit lcrf.org.

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.

GLOSSARY

Biomarker

A biologic molecule that can be used to measure the presence or progress of disease or the effects of treatment.

Biomarker-driven treatment

A type of treatment that is designed to block the action of abnormal genes or proteins that may be contributing to cancer growth. For people whose tumors test positive for a certain biomarker, it may be possible to base their treatment plan on that biomarker.

Biomarker testing

A test that checks for certain genes, proteins, or other molecules in a sample of tissue, blood, or other body fluid. Biomarker tests also check for certain changes in a gene or chromosome that may cause cancer to form. Results can be used to help plan treatment. Also called genetic testing or molecular testing.

Epidermal growth factor receptor (EGFR)

A protein on the surface of a cell that when activated, sends signals for the cell to grow and divide. EGFR is found at abnormally high levels on the surface of many types of cancer cells, which may cause them to divide excessively.

Gene

Coded instructions in cells for making new cells and controlling how cells behave.

Genetic testing

See “Biomarker testing.”

Molecular testing

See “Biomarker testing.”

Mutation

Abnormal change in coded instructions within cells (genes).

Please see Important Safety Information on pages 30-31.

Click for the [Full Prescribing Information](#) and [Patient Information](#) or visit VIZIMPRO.com.



TIPS FOR MANAGING YOUR DIAGNOSIS

✓ Write things down

- A new diagnosis brings with it a lot of information, which can be overwhelming. Write down any questions or concerns you have, so you can remember to ask them at your next visit
- It's also helpful to capture important information given by your healthcare team, so you can refer to it later when you have had time to process things. Don't hesitate to ask a care partner to help take notes during visits

✓ Stay organized

- Consider keeping a folder or binder to help store and organize your medical records and other materials from your healthcare team
- Making a list of all your doctors and their contact information is also helpful to have on hand

✓ Talk with your doctor

- Open and honest conversations with your healthcare team are important to make sure your treatment plan addresses your needs and preferences. It's also important to have your voice heard and share in the decision-making process with your healthcare team
- Nervous about sharing your thoughts and feelings with your doctor? Let your care partner know, and ask them to help guide conversations with your doctors

✓ Find or build a support network

- Coping with a new diagnosis doesn't have to be done alone. Consider joining a support group to connect with other people who understand exactly what you're going through

Visit [VIZIMPRO.com](https://www.vizimpro.com)